Gilead Sciences to Release First Quarter 2021 Financial Results on Thursday, April 29, 2021Business Wire • 04/15/21
Everest Medicines Announces that the US FDA has Granted Licensing Partner Gilead Sciences, Inc. Accelerated Approval of Trodelvy® for the Treatment of Metastatic Urothelial CancerPRNewsWire • 04/14/21
U.S. FDA Grants Accelerated Approval to Trodelvy® for the Treatment of Metastatic Urothelial CancerBusiness Wire • 04/13/21
Everest Medicines Announces that Licensing Partner Gilead Sciences, Inc. has Received Full US FDA Approval of Trodelvy® for the Treatment of Previously Treated Unresectable Locally Advanced or Metastatic Triple-Negative Breast CancerPRNewsWire • 04/09/21
Biotech Stocks Could Use A Win — Will The First Quarter Offer That?Investors Business Daily • 04/08/21
FDA Approves Trodelvy®, the First Treatment for Metastatic Triple-Negative Breast Cancer Shown to Improve Progression-Free Survival and Overall SurvivalBusiness Wire • 04/07/21
Kite Submits Supplemental Biologics License Application to U.S. Food and Drug Administration for Tecartus® in Adult Patients With Relapsed or Refractory Acute Lymphoblastic LeukemiaBusiness Wire • 04/01/21
Gilead Sciences' Reported Earnings Highlight The Importance Of Reading Footnotes – Filing Season 2021 RecapForbes • 04/01/21
Booking, Expedia, FuelCell, Plug Power, Roku and More of Tuesday Afternoon Analyst Calls24/7 Wall Street • 03/30/21